LANGHORNE, Pa., April 15, 2026
Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its Biologics License Application (BLA) for molgramostim inhalation solution in the treatment of autoimmune pulmonary alveolar proteinosis (PAP). The Prescription Drug User Fee Act (PDUFA) target action date has been extended by three months to November 22, 2026, reflecting the agency’s need for additional time to review recently submitted information.
The extension follows the FDA’s determination that Savara’s responses to prior information requests constituted a major amendment to the BLA, which triggered the timeline extension. Importantly, the agency did not raise any concerns regarding safety, efficacy, or manufacturing, reinforcing confidence in the overall data package supporting molgramostim. This regulatory update represents a critical step in the approval process for a therapy targeting a rare and underserved pulmonary condition.
Regulatory Progress Strengthens Path to Approval
The FDA is currently reviewing molgramostim under Priority Review, a designation reserved for therapies that could offer significant improvements in the treatment of serious conditions. The extension allows the agency additional time to evaluate the newly submitted data, ensuring a comprehensive review of the application.
Molgramostim has already received multiple regulatory recognitions, including Fast Track and Breakthrough Therapy Designations in the United States, as well as Orphan Drug Designation from both the FDA and the European Medicines Agency (EMA). Additionally, the therapy has been granted Innovation Passport and Promising Innovative Medicine designations by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Advertisement
These designations collectively highlight the strong clinical and scientific rationale behind molgramostim and underscore its potential to address a significant unmet medical need. The continued engagement with global regulatory authorities further positions Savara for potential approvals across multiple regions.
Targeting a Rare and Serious Lung Disease
Autoimmune pulmonary alveolar proteinosis (PAP) is a rare and debilitating lung disorder characterized by the accumulation of surfactant within the alveoli, impairing gas exchange and leading to symptoms such as shortness of breath, fatigue, and increased risk of lung infections. The disease occurs due to the presence of autoantibodies that neutralize granulocyte-macrophage colony-stimulating factor (GM-CSF), a critical protein required for the proper functioning of alveolar macrophages responsible for clearing surfactant.
Molgramostim is a recombinant human GM-CSF therapy designed to restore this essential biological pathway. Delivered via an investigational eFlow® Nebulizer System, the therapy enables targeted inhalation directly into the lungs, enhancing its therapeutic potential while minimizing systemic exposure.
By addressing the underlying cause of autoimmune PAP, molgramostim has the potential to significantly improve lung function and overall quality of life for affected patients, many of whom currently have limited treatment options. In severe cases, the disease can lead to complications such as lung fibrosis or the need for lung transplantation, highlighting the urgency for effective therapies.